Fingolimod for relapsing-remitting multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, April 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 22,353 followers.

Le fingolimod pour la sclérose en plaques récurrente-rémittente https://t.co/e3eTmT6c5h

#Fingolimodi vähentää aaltomaisen #MS taudin pahenemisvaiheita. Vaikutus toimintakykyyn vielä epäselvää. #mstauti https://t.co/UOvbVp4W3E

RT @rincondesisifo: (Cochrane) Fingolimod en EM remitente recurrente vs IFN beta 1 https://t.co/xUgzcNwTK2

(Cochrane) Fingolimod en EM remitente recurrente vs IFN beta 1 https://t.co/xUgzcNwTK2

Fingolimod for relapsing-remitting multiple sclerosis. - PubMed - NCBI https://t.co/OkWpRolFmc

Fingolimod for relapsing-remitting multiple sclerosis. https://t.co/iLYfTeziiM

Cochrane Review of Fingolimod (Gilenya) for RRMS https://t.co/5Fh6NmyqAB

Fingolimod for relapsing-remitting multiple sclerosis - https://t.co/9lobMl9eMc #GoogleAlerts